P027 Are skin cancer teaching ‘super clinics’ safe and effective? Results of a UK pilot study

Huw Greenish,Hafsa Faarax Shirwac,Hannah Morgan,Harry Heath,Sarah Carswell,Alexander D G Anderson

DOI: https://doi.org/10.1093/bjd/ljae090.054

IF: 11.113

2024-06-28

British Journal of Dermatology

Abstract:Abstract The ‘super clinic’ model is a response to skin cancer capacity pressures facing the NHS and the need to deliver educational opportunities and supervision to trainees, specialty and specialist (SAS) doctors and specialist nurses. This model involves a single specialist supervising multiple trainees and personally reviewing a high number of patients. It is unknown whether the rapid decision making inherent in this way of working affects clinical performance. This pilot study aimed to assess the implementation of an educational super clinic in an NHS hospital dermatology department and to compare performance against standard practice. Super clinics were run over a 6-month period in 2022. A single permanent associate specialist oversaw up to three trainees, each of whom had their own list of cases. Patients were referred via the suspected skin cancer pathway. After reviewing each patient, trainees presented relevant findings and a working diagnosis to the specialist, who examined the patient, then confirmed the diagnosis and agreed a management plan. All patients were offered a full skin check. Both standard and super clinics lasted 3–4 h. Electronic patient records and histology results were reviewed to establish ultimate diagnoses. The proportions of patients in whom histology was obtained and any form of skin cancer was ultimately diagnosed were compared with data from the same specialist’s standard 2-week-wait clinics during the study period. In total, 345 patients were seen in 12 super clinics (average 29 patients per clinic, maximum 41), while 589 patients were seen in standard clinics (14 patients per clinic) over the same period (no trainees present). Clinicians under supervision included two dermatology ST3 doctors, one dermatology trust grade doctor, one genitourinary medicine consultant, three ST1–2 doctors and two clinical nurse specialists. Histology was obtained in 174 of 345 (50%) patients in the super clinic group vs. 262 of 589 (44%) in the regular clinic group (P = 0.08). There was no significant difference in the number of patients ultimately diagnosed with a malignancy in the super clinics (100 of 345, 29%) vs. the regular clinics (159 of 589, 27%) (P = 0.51). The super clinic model facilitated face-to-face supervision and education for multiple trainees, while simultaneously more than doubling new patient capacity. Compared with standard clinics, there was no negative impact on the specialist’s diagnostic confidence (histology rate) or cancer pick up rate. These findings suggest that the super clinic model is both safe and effective.

dermatology